Q1 2022 13F Holders as of 3/31/2022
-
Type / Class
-
Equity / COMMON STOCK
-
Shares outstanding
-
106M
-
Number of holders
-
70
-
Total 13F shares, excl. options
-
23.3M
-
Shares change
-
+23.3M
-
Total reported value, excl. options
-
$299M
-
Value change
-
+$299M
-
Put/Call ratio
-
0.09
-
Number of buys
-
68
-
Price
-
$12.85
Significant Holders of Amylyx Pharmaceuticals, Inc. - COMMON STOCK (AMLX) as of Q1 2022
75 filings reported holding AMLX - Amylyx Pharmaceuticals, Inc. - COMMON STOCK as of Q1 2022.
Amylyx Pharmaceuticals, Inc. - COMMON STOCK (AMLX) has 70 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 23.3M shares
of 106M outstanding shares and own 21.94% of the company stock.
Largest 10 shareholders include VIKING GLOBAL INVESTORS LP (7.17M shares), Bain Capital Life Sciences Investors, LLC (2.76M shares), BOXER CAPITAL, LLC (2.2M shares), PERCEPTIVE ADVISORS LLC (1.47M shares), Rock Springs Capital Management LP (998K shares), VANGUARD GROUP INC (992K shares), Verition Fund Management LLC (925K shares), TYBOURNE CAPITAL MANAGEMENT (HK) LTD (769K shares), 683 Capital Management, LLC (678K shares), and Alpha Wave Global, LP (617K shares).
This table shows the top 70 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.